| | | Great job Bullish, XPEL was and continues to be a fantastic pick! Looking forward to an up-listing on Nasdaq to increase visibility and liquidity. This, combined with the revenues and margins will give us a great 1, 2, 3, 4 punch for coming periods.
IPA. Agree with your comments about the insider selling have an impact on the share price, but you and i know that the insider selling is fully explainable and has NOTHING to do w/ IPA's prospects. People are free to regard IPA however they wish, or not at all.
But my suggestion would be to read last week's NR very carefully, and revisit the IPA presentation in the co. website that ends with expectations of "significant contracts" this new fiscal year and uplisting to Nasdaq activities in Q1/Q2 2019.
The previous year 2017/18 we did under $3 million in revenues. This year, 2018/19, some people feel we'll do $6.5 million in revenues and I like this number. You do not get onto Nasdaq with $6.5m in revenues (some peoples' forecast for this year) and million dollar losses, so management is signalling something very clearly in their bold presentation. For those that don't know the IPA full service B cell facility is the only one in the Industry - and what a multi billion dollar growth industry it is.
The next financials will just take us to year end April 30. The opening of the B Cell full service facility was only NR'd on April 27 so there will be very minor, if any, B cell revenues. What should be extremely interesting is the Subsequent Events of the MD&A, which should give us a better indication of the industry interest. |
|
